These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 24998153)

  • 1. Dapagliflozin--do we need it registered for type 2 diabetes?
    Doggrell SA; Tuli R
    Expert Opin Pharmacother; 2014 Aug; 15(11):1631-5. PubMed ID: 24998153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comment and response to: dapagliflozin - do we need it registered for type 2 diabetes?
    Jabbour S
    Expert Opin Pharmacother; 2014 Dec; 15(18):2751-2. PubMed ID: 25346092
    [No Abstract]   [Full Text] [Related]  

  • 3. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
    Jabbour SA; Hardy E; Sugg J; Parikh S;
    Diabetes Care; 2014; 37(3):740-50. PubMed ID: 24144654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes.
    Rosenstock J; Perl S; Johnsson E; García-Sánchez R; Jacob S
    Diabetes Obes Metab; 2019 Sep; 21(9):2152-2162. PubMed ID: 31144431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Author’s response.
    Doggrell S
    Expert Opin Pharmacother; 2014 Dec; 15(18):2752-3. PubMed ID: 25562079
    [No Abstract]   [Full Text] [Related]  

  • 6. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects.
    Kasichayanula S; Liu X; Shyu WC; Zhang W; Pfister M; Griffen SC; Li T; LaCreta FP; Boulton DW
    Diabetes Obes Metab; 2011 Jan; 13(1):47-54. PubMed ID: 21114603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empagliflozin/metformin fixed-dose combination: a review in patients with type 2 diabetes.
    Hu J; Zou P; Zhang S; Zhou M; Tan X
    Expert Opin Pharmacother; 2016 Dec; 17(18):2471-2477. PubMed ID: 27819159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Oral add-on therapy to metformin in type 2 diabetes mellitus: a direct comparison between canagliflozin and sitagliptin].
    Schnell O
    Dtsch Med Wochenschr; 2014 Feb; 139 Suppl 2():S70-4. PubMed ID: 24481636
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study.
    Jabbour SA; Frías JP; Guja C; Hardy E; Ahmed A; Öhman P
    Diabetes Obes Metab; 2018 Jun; 20(6):1515-1519. PubMed ID: 29316164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes.
    Cai X; Shi L; Yang W; Gu S; Chen Y; Nie L; Ji L
    J Med Econ; 2019 Apr; 22(4):336-343. PubMed ID: 30663458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching from sulphonylurea to a sodium-glucose cotransporter2 inhibitor in the fasting month of Ramadan is associated with a reduction in hypoglycaemia.
    Wan Seman WJ; Kori N; Rajoo S; Othman H; Mohd Noor N; Wahab NA; Sukor N; Mustafa N; Kamaruddin NA
    Diabetes Obes Metab; 2016 Jun; 18(6):628-32. PubMed ID: 26889911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin.
    Hayashi T; Fukui T; Nakanishi N; Yamamoto S; Tomoyasu M; Osamura A; Ohara M; Yamamoto T; Ito Y; Hirano T
    Cardiovasc Diabetol; 2017 Jan; 16(1):8. PubMed ID: 28086872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-related quality of life (EQ-5D) among type 2 diabetes mellitus patients treated with dapagliflozin over 2 years.
    Grandy S; Langkilde AM; Sugg JE; Parikh S; Sjöström CD
    Int J Clin Pract; 2014 Apr; 68(4):486-94. PubMed ID: 24499168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin.
    Ljunggren Ö; Bolinder J; Johansson L; Wilding J; Langkilde AM; Sjöström CD; Sugg J; Parikh S
    Diabetes Obes Metab; 2012 Nov; 14(11):990-9. PubMed ID: 22651373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of the treatment with dapagliflozin and metformin compared to metformin monotherapy for weight loss in patients with class III obesity: a randomized controlled trial.
    Ferreira-Hermosillo A; Molina-Ayala MA; Molina-Guerrero D; Garrido-Mendoza AP; Ramírez-Rentería C; Mendoza-Zubieta V; Espinosa E; Mercado M
    Trials; 2020 Feb; 21(1):186. PubMed ID: 32059692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-glucose cotransporter 2 inhibitors: the new option for diabetes mellitus management.
    Powell J; Miller SA; Taylor JR
    South Med J; 2015 Feb; 108(2):82-90. PubMed ID: 25688892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [XIGDUO - fixed combination of the active ingredients dapagliflozin and metformin].
    Edelsberger T
    Vnitr Lek; 2016 Mar; 62(3):199-201. PubMed ID: 27180669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empagliflozin/linagliptin single-pill combination therapy for patients with type 2 diabetes mellitus.
    Jain RK
    Expert Opin Pharmacother; 2017 Apr; 18(6):545-549. PubMed ID: 28375658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial.
    Fadini GP; Bonora BM; Zatti G; Vitturi N; Iori E; Marescotti MC; Albiero M; Avogaro A
    Cardiovasc Diabetol; 2017 Apr; 16(1):42. PubMed ID: 28376855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A real-world analysis of glycemic control among patients with type 2 diabetes treated with canagliflozin versus dapagliflozin.
    Blonde L; Patel C; Bookhart B; Pfeifer M; Chen YW; Wu B
    Curr Med Res Opin; 2018 Jun; 34(6):1143-1152. PubMed ID: 29595326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.